Drug news
Minophagen extends marketing rights to bexarotene for T-Cell Lymphoma
Minophagen Pharma has acquired further rights to market the synthetic retinoid bexarotene from Eisai. Minophagen has added to its rights to market in Japan the territories of Asia, Oceana, the Middle East and Eastern Europe.The drug is marketed in 20 countries for refractory/recurrent T-Cell Lymphoma and in the USA by Eisai as Targretin.